Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Adherium Ltd. ( (AU:ADR) ).
Adherium Limited reported a 60% increase in operating revenue to $801,402 for the six months ended 31 December 2025, up from $500,328 a year earlier, reflecting growing commercial traction for its digital health offerings. Despite the stronger top line, the company’s net loss from ordinary activities widened slightly by 1.5% to $5.86 million, and its net tangible assets per share remained negative, underscoring ongoing funding and scale-up challenges for shareholders as the business continues to invest for growth.
The interim filing showed no dividends declared or dividend reinvestment plan in place, and the group reported no changes in control of entities, associates, or joint ventures over the half year. The results highlight a business still in a development and investment phase, prioritising revenue growth and market position over near-term profitability, with equity holders bearing the impact of continued losses and negative net tangible asset backing per share.
The most recent analyst rating on (AU:ADR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Adherium Ltd. stock, see the AU:ADR Stock Forecast page.
More about Adherium Ltd.
Adherium Limited is a healthcare technology company that develops and commercialises digital health solutions, with a focus on connected respiratory devices and adherence monitoring for patients and clinicians. The company targets global healthcare markets where remote monitoring, data-driven care, and improved medication adherence can reduce costs and improve outcomes.
Technical Sentiment Signal: Sell
Current Market Cap: A$15.63M
For a thorough assessment of ADR stock, go to TipRanks’ Stock Analysis page.